Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m2 i.v. for four consecutive weekly administra...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2011/258689 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564557764100096 |
|---|---|
| author | Filippo Francini Alessandra Pascucci Edoardo Francini Gianluca Bargagli Raffaele Conca Antonella Licchetta Giandomenico Roviello Ignazio Martellucci Giorgio Chiriacò Salvatora Tindara Miano Giuseppe Marzocca Antonio Manganelli Roberto Ponchietti Vinno Savelli Roberto Petrioli |
| author_facet | Filippo Francini Alessandra Pascucci Edoardo Francini Gianluca Bargagli Raffaele Conca Antonella Licchetta Giandomenico Roviello Ignazio Martellucci Giorgio Chiriacò Salvatora Tindara Miano Giuseppe Marzocca Antonio Manganelli Roberto Ponchietti Vinno Savelli Roberto Petrioli |
| author_sort | Filippo Francini |
| collection | DOAJ |
| description | Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m2 i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks. Results. Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy. |
| format | Article |
| id | doaj-art-a1065ac7a88d406a9d014508519fdb43 |
| institution | Kabale University |
| issn | 2090-3111 2090-312X |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-a1065ac7a88d406a9d014508519fdb432025-02-03T01:10:43ZengWileyProstate Cancer2090-31112090-312X2011-01-01201110.1155/2011/258689258689Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to DocetaxelFilippo Francini0Alessandra Pascucci1Edoardo Francini2Gianluca Bargagli3Raffaele Conca4Antonella Licchetta5Giandomenico Roviello6Ignazio Martellucci7Giorgio Chiriacò8Salvatora Tindara Miano9Giuseppe Marzocca10Antonio Manganelli11Roberto Ponchietti12Vinno Savelli13Roberto Petrioli14Department of Odontostomatology and Maxillo-Facial Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyGeneral Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyUrologic Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyGenitourinary Unit, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyDepartment of Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyMedical Oncology, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, ItalyBackground. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m2 i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks. Results. Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.http://dx.doi.org/10.1155/2011/258689 |
| spellingShingle | Filippo Francini Alessandra Pascucci Edoardo Francini Gianluca Bargagli Raffaele Conca Antonella Licchetta Giandomenico Roviello Ignazio Martellucci Giorgio Chiriacò Salvatora Tindara Miano Giuseppe Marzocca Antonio Manganelli Roberto Ponchietti Vinno Savelli Roberto Petrioli Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel Prostate Cancer |
| title | Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel |
| title_full | Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel |
| title_fullStr | Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel |
| title_full_unstemmed | Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel |
| title_short | Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel |
| title_sort | bevacizumab and weekly docetaxel in patients with metastatic castrate resistant prostate cancer previously exposed to docetaxel |
| url | http://dx.doi.org/10.1155/2011/258689 |
| work_keys_str_mv | AT filippofrancini bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT alessandrapascucci bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT edoardofrancini bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT gianlucabargagli bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT raffaeleconca bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT antonellalicchetta bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT giandomenicoroviello bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT ignaziomartellucci bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT giorgiochiriaco bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT salvatoratindaramiano bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT giuseppemarzocca bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT antoniomanganelli bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT robertoponchietti bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT vinnosavelli bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel AT robertopetrioli bevacizumabandweeklydocetaxelinpatientswithmetastaticcastrateresistantprostatecancerpreviouslyexposedtodocetaxel |